Literature DB >> 14724651

Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration.

T Yokoyama, K Miyazawa, E Kurakawa, A Nagate, T Shimamoto, K Iwaya, S Akata, M Aoshima, H Serizawa, K Ohyashiki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14724651     DOI： 10.1038/sj.leu.2403251

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Authors:  Koichiro Suemori; Hiroshi Fujiwara; Seiichiro Watanabe; Taichi Azuma; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2010-11-26       Impact factor: 2.490

2.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

3.  Interstitial pneumonitis in a patient with chronic myeloid leukemia.

Authors:  Ahmet Emre Eşkazan; Ayşe Salihoğlu; Serdar Erturan; Teoman Soysal
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

4.  Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.

Authors:  Seong Woo Go; Boo Kyeong Kim; Sung Hak Lee; Tae-Jung Kim; Joo Yeon Huh; Jong Min Lee; Jick Hwan Hah; Dong Whi Kim; Min Jung Cho; Tae Wan Kim; Ji Young Kang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-12-24

5.  A case of imatinib-related obstructive bronchiolitis followed long term.

Authors:  Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe
Journal:  Respir Med Case Rep       Date:  2020-04-04

6.  Nilotinib-induced interstitial lung disease.

Authors:  Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myung Hee Kang; Jeong-Hee Lee; Hoon-Gu Kim
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

Review 7.  Repurposing of Kinase Inhibitors for Treatment of COVID-19.

Authors:  Ellen Weisberg; Alexander Parent; Priscilla L Yang; Martin Sattler; Qingsong Liu; Qingwang Liu; Jinhua Wang; Chengcheng Meng; Sara J Buhrlage; Nathanael Gray; James D Griffin
Journal:  Pharm Res       Date:  2020-08-10       Impact factor: 4.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.